Nasdaq · Healthcare
FATE THERAPEUTICS INC (FATE)
As-reported financials and recent SEC filings for FATE THERAPEUTICS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$6.6M
Net income
$-136.3M
Net margin
—
Diluted EPS
$-1.15
ROE
-65.8%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M |
| Gross profit | — | — | — | — | — |
| Operating income | $-147.7M | $-210.3M | $-190.5M | $-308.4M | $-217.0M |
| Net income | $-136.3M | $-186.3M | $-160.9M | $-281.7M | $-212.2M |
| Diluted EPS | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →32026-06-15
View on EDGAR →Largest Healthcare peers
Go deeper on FATE
Search FATE THERAPEUTICS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.